Atorvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H35FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0JWA85V8F, chemically known as 1h-pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (r-(r*,r*))- but generally known as atorvastatin, which bears US NIH Compound Identifier 60823. Atorvastatin most often comes in base, calcium, and lactone forms. European Medicines Agency schedules Atorvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05600MIG. The term ATORVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules atorvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. ATORVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atorvastatin under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN remains the US FDA Preferred Term for this commodity. Atorvastatin bears US NLM identifiers UMLS ID C0286651 and NCI Concept Code C61527. SMILES: FC1CCC(C2N(C(C(C)C)C(C2C2CCCCC2)C(=O)NC2CCCCC2)CCC(O)CC(O)CC(=O)O)CC1.